Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PRAN

Alterity Therapeutics (PRAN) Stock Price, News & Analysis

Alterity Therapeutics logo

About Alterity Therapeutics Stock (NASDAQ:PRAN)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$3.14
$3.38
50-Day Range
$0.95
$2.06
52-Week Range
$1.09
$2.91
Volume
35,085 shs
Average Volume
130,956 shs
Market Capitalization
$28.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Remove Ads
Receive PRAN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alterity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRAN Stock News Headlines

Trump Allies Confirm Exec Order 14024 Triggers Dollar Collapse
Executive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement. When the dollar collapses, your savings could disappear overnight. With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar.
Alterity Therapeutics Ltd PBN
Alterity Therapeutics to List New Securities on ASX
Alterity Therapeutics raises A$40M in placement
See More Headlines

PRAN Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Alterity Therapeutics investors own include Meta Platforms (META), Novavax (NVAX), Catalyst Pharmaceuticals (CPRX), Intercept Pharmaceuticals (ICPT), Rigel Pharmaceuticals (RIGL), Arena Pharmaceuticals (ARNA) and Conatus Pharmaceuticals (CNAT).

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRAN
Fax
N/A
Employees
14
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$150,000.00
Price / Cash Flow
N/A
Book Value
$1.40 per share
Price / Book
2.46

Miscellaneous

Free Float
N/A
Market Cap
$30.71 million
Optionable
Not Optionable
Beta
1.05
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report

This page (NASDAQ:PRAN) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners